PRACA ORYGINALNA
Czy stosować statyny u pacjentów z chorobą wątroby ? Omówienie na podstawie opisu przypadku
 
Więcej
Ukryj
1
Z Katedry i Kliniki Chorób Wewnętrznych Uniwersytetu Medycznego w Lublinie
 
Med Og. 2010;16(3):361–365
SŁOWA KLUCZOWE
STRESZCZENIE ARTYKUŁU
W pracy na podstawie opisu pacjenta z niealkoholową chorobą wątroby, omówiono wskazania i przeciwskazania do stosowania statyn u chorych z uszkodzeniem wątroby.

A patient was admitted to the Clinic due to symptoms of type 2 diabetes and arterial hypertension. Based on the results of laboratory tests and imaging examinations, non-alcoholic fatty liver disease was diagnosed. Despite the features of liver damage the patient was treated with statin. Based on the case presented, indications and contraindications were discussed for the application of statins in patients with liver impairment.
 
REFERENCJE (6)
1.
Abel T., Feher J., Dinja E., Eldin MG, Kovacs A.: Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009, 15, MS 6-11.
 
2.
Ahmed MH. Rosuvastin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH). Scand J Gastroenterol 2006, 41, 631.
 
3.
Cohen DE, Anania FA, Chalasani N.: An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97, 77C-81C.
 
4.
De Denus S., Spinler S.A., Miller K, Peterson AM.: Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004, 24, 584-591.
 
5.
Gomez-Dominguez E., Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L., Moreno-Otero R.: A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients, Alimentary Pharmacology & Therapeutics 23, 2006, 1643 – 1647.
 
6.
Smith CC., Bernstein LI., Davis RB., Rind DM., Shmerling RH.: Screening for Statin-Related Toxicity. The Yield of Transaminase and Creatine Kinase Measurements in Primary Care Setting, Arch Intern Med 2003, 163, 688-692.
 
eISSN:2084-4905
ISSN:2083-4543